z-logo
open-access-imgOpen Access
Experimental and clinical aspects of the pathogenesis of endotoxin shock
Author(s) -
N. R. Ivanov,
B. Z. Shankman
Publication year - 1984
Publication title -
kazanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2587-9359
pISSN - 0368-4814
DOI - 10.17816/kazmj89402
Subject(s) - septic shock , antibiotics , medicine , disease , shock (circulatory) , immunology , intensive care medicine , infectious disease (medical specialty) , pathogenesis , diagnostic test , infectious agent , sepsis , pathology , biology , pediatrics , microbiology and biotechnology
The occurrence of a shock-like state in connection with an infectious disease was first reported by Laennek in 1831. More specifically, this relationship was established in 1899 [46]. The absence of a noticeable decrease in the frequency of recorded endotoxin shock in humans is due to a number of factors, the most important among which are the following: a) improvement in the diagnosis of endotoxin shock, made possible by the use of sophisticated diagnostic equipment; b) familiarity of specialists of various profiles with this nosological form; c) an increase in the life expectancy of patients with severe pathology and a decrease in general and immunological reactivity; d) the use of immunosuppressants and cytostatic drugs for allergies, malignant neoplasms, which facilitates the development of infectious pathology; e) frequent obstetric pathology, accompanied by the birth of children with reduced resistance; f) widespread use of antibiotic therapy, leading to the emergence of antibiotic-resistant microbes; it should also be noted here that when treating septic foci and infectious diseases with antibiotics, there is a danger of massive entry into the bloodstream of endotoxins released from dead microorganisms; g) carrying out complex diagnostic manipulations and surgical operations that open the entrance gates for infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here